Patent protection will run out later this decade for many multibillion-dollar medicines, forcing their large pharmaceutical makers to find new products and markets. Explore market trends in
this Trendline.
The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.
A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug Wegovy two years after reporting initial Phase 3 results.
Health secretary Robert F. Kennedy Jr. has ordered a drastic downsizing of HHS that employees and critics say risks degrading essential services and functions.
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene beforehand with a targeted medication.
A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.
Without in-house expertise, navigating the complexities of radiopharmaceutical trials can be overwhelming. Examine the roadmap from clinical development to commercialization in this playbook.
